2024
Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
Goldberg L, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Guru Murthy G, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Cursio J, Patel A. Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors. Blood 2024, 144: 1787-1787. DOI: 10.1182/blood-2024-197898.Peer-Reviewed Original ResearchIsocitrate dehydrogenase inhibitorsMedian OSMPN-AP/BPIntensive chemotherapyMyeloproliferative neoplasmsHypomethylating agentsEuropean LeukemiaNetAcute myeloid leukemiaMPN-BPComplete remissionOverall survivalCytogenetic responsePartial remissionBlast phaseTen ptsCo-mutationsIncidence of driver mutationsVariable risk of progressionAchievement of complete remissionAllogeneic stem cell transplantationAssociated with poor overall survivalCohort of ptsIDH1 inhibitor ivosidenibIDH2 inhibitor enasidenibIncomplete count recoveryClinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
Cohen-Nowak A, Coltoff A, Patel A, Atallah E, El Kettani M, Wang J, Symes E, Venkataraman G, Siddon A, Giever E, Shallis R, Altman J, Bell-Burdett K, Badar T, Aqil B, Abaza Y. Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study. Blood 2024, 144: 2801-2801. DOI: 10.1182/blood-2024-199377.Peer-Reviewed Original ResearchALL-directed therapySubtypes of acute leukemiaOverall survivalIntensive chemotherapyAcute lymphoblastic leukemiaAcute myeloid leukemiaAllo-SCTOS ratesAcute leukemiaFLT3-ITDBridge to allogeneic stem cell transplantationBlast populationCNS diseaseMedian duration of responseAllogeneic stem cell transplantationMulti-center retrospective studyResistant to traditional therapiesAML-directed therapyDiagnosis of MPALMedian overall survivalIncomplete count recoveryInduce durable remissionsDuration of responseStem cell transplantationAllo-SCT recipientsGene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
Kiwan A, Kewan T, Xu M, Siddon A, Girardi M, Sethi T, Foss F. Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes. Blood 2024, 144: 4440-4440. DOI: 10.1182/blood-2024-205144.Peer-Reviewed Original ResearchGene copy number alterationsAssociated with poor OSAbsolute lymphocyte countFluorescence in situ hybridization panelAssociated with worse OSCirculating tumor cellsFluorescence in situ hybridizationOverall survivalCopy number alterationsT cell receptorPoor OSSurvival outcomesTumor cellsMedian OSCox proportional hazardsBlood involvementATM deletionArid1a deletionT cellsElevated absolute lymphocyte countMedian absolute lymphocyte countAssociated with better OSMedian age of patientsMultivariate CPH modelZEB1 deletionOverall survival in TP53-mutated AML and MDS
Puzo C, Hager K, Rinder H, Weinberg O, Siddon A. Overall survival in TP53-mutated AML and MDS. Annals Of Hematology 2024, 1-11. PMID: 39443370, DOI: 10.1007/s00277-024-06054-7.Peer-Reviewed Original ResearchOverall survivalBlast countTP53 mutationsSignificant predictors of OSP53 mutation typePredictors of OSAggressive disease biologyRetrospective chart reviewKaplan-Meier curvesYale-New Haven HospitalNext generation sequencingCox proportional hazards modelsProportional hazards modelComplex karyotypePoor OSP53 mutationsWHO criteriaChart reviewNew Haven HospitalPoor prognosisCo-mutationsPathogenic mutationsAMLICCS guidelinesMutation type
2023
Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group
de M, Wu L, Hirt C, Pihan G, Patel S, Tam W, Bueso-Ramos C, Kanagal-Shamanna R, Raess P, Siddon A, Narayanan D, Morgan E, Pinkus G, Mason E, Hsi E, Rogers H, Toth L, Foucar K, Hurwitz S, Bagg A, Rets A, George T, Orazi A, Arber D, Hasserjian R, Weinberg O, Group F. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leukemia & Lymphoma 2023, 64: 972-980. PMID: 36960680, DOI: 10.1080/10428194.2023.2185091.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaOverall survivalNPM1 mutationsDe novo acute myeloid leukemiaBone Marrow Pathology GroupMulti-institutional cohort studyNovo acute myeloid leukemiaRetrospective multi-institutional cohort studyShorter overall survivalPoor overall survivalFrequent cytogenetic abnormalityCohort studyMyeloid leukemiaPathology groupCytogenetic abnormalitiesComplex karyotypeUnique genetic landscapeMutations of genesGene mutationsSarcomaGenetic landscapeHigher average numberMutationsLeukemia
2022
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Weinberg OK, Siddon A, Madanat Y, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Advances 2022, 6: 2847-2853. PMID: 35073573, PMCID: PMC9092405, DOI: 10.1182/bloodadvances.2021006239.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeOverall survivalTP53 mutationsComplex karyotypeBlast countWorse outcomesTherapy-related MDS/acute myeloid leukemiaDiagnosis of AMLMDS/acute myeloid leukemiaTherapy-related myeloid neoplasmsTherapy-related casesTP53-mutated patientsDe novo diseaseMarrow blast countLower hemoglobin levelsWorse overall survivalCK patientsNovo diseaseDifferent disease categoriesClinicopathologic featuresHemoglobin levelsMDS patientsMultivariable analysisAggressive disease
2020
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplant
2015
Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia
Schulz W, Durant T, Rinder H, Tormey C, Torres R, Smith B, Hager K, Howe J, Siddon A. Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia. Blood 2015, 126: 1385. DOI: 10.1182/blood.v126.23.1385.1385.Peer-Reviewed Original ResearchDe novo acute myeloid leukemiaNovo acute myeloid leukemiaAcute myeloid leukemiaMolecular clonalityAML patientsTumor heterogeneityMyeloid leukemiaNext-generation sequencingNormal-risk subjectsAdverse prognostic indicatorTime of diagnosisFurther prospective studiesLong-term outcomesFLT3-ITD mutationHigh-risk groupChoice of therapyFirst prospective evidenceLimited clinical utilityHigh-risk classificationEarly survivalStudy patientsOverall survivalPatient agePatient subsetsInitial diagnosis